{"disease":{"id":"cholangitis","name":"Cholangitis","therapeutic_area":"","data":{},"enrichment_level":0,"last_enriched_at":null,"visit_count":0,"created_at":"2026-04-19T18:31:21.150Z","updated_at":"2026-04-19T18:39:44.960Z","meddra_pt":null,"meddra_code":null,"icd10_codes":null,"synonyms":[],"prevalence_global":null,"prevalence_us":null,"marketed_drug_count":12,"pipeline_drug_count":0,"trial_count":9},"drugs":{"marketed":[{"drug_id":"seladelpar","indication_name":"primary biliary cholangitis (PBC)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Livdelzi","generic_name":"SELADELPAR","company_name":"Gilead Sciences Inc","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":64,"revenue":"200","mechanism":"Livdelzi works by inhibiting the activity of a specific enzyme involved in the progression of liver disease."},{"drug_id":"seladelpar","indication_name":"Primary Biliary Cholangitis (PBC)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Livdelzi","generic_name":"SELADELPAR","company_name":"Gilead Sciences Inc","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":64,"revenue":"200","mechanism":"Livdelzi works by inhibiting the activity of a specific enzyme involved in the progression of liver disease."},{"drug_id":"gentamicin","indication_name":"Cholangitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Garamycin","generic_name":"GENTAMICIN","company_name":"Merck & Co.","drug_phase":"marketed","molecular_target":"Transient receptor potential cation channel subfamily V member 5","drug_class":"Aminoglycoside Antibacterial","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"erythromycin-ethyl-succinate","indication_name":"Cholangitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Eryped","generic_name":"Erythromycin ethyl succinate","company_name":"Arbor Pharms Llc","drug_phase":"marketed","molecular_target":"","drug_class":"Macrolide","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"cefazolin","indication_name":"Cholangitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Ancef In Sodium Chloride 0.9% In Plastic Container","generic_name":"CEFAZOLIN","company_name":"GSK","drug_phase":"marketed","molecular_target":"","drug_class":"Cephalosporin Antibacterial","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"cefazolin-sodium","indication_name":"Cholangitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Ancef In Sodium Chloride 0.9% In Plastic Container","generic_name":"Cefazolin Sodium","company_name":"GSK","drug_phase":"marketed","molecular_target":"Bacterial cell wall peptidoglycan","drug_class":"Cephalosporin","quality_score":60,"revenue":null,"mechanism":"Cefazolin is an antibacterial drug that inhibits bacterial cell wall synthesis."},{"drug_id":"ampicillin","indication_name":"Cholangitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Unasyn","generic_name":"AMPICILLIN","company_name":"Bristol-Myers Squibb","drug_phase":"marketed","molecular_target":"Transient receptor potential cation channel subfamily M member 4","drug_class":"Penicillin-class Antibacterial","quality_score":53,"revenue":null,"mechanism":""},{"drug_id":"sulbactam","indication_name":"Cholangitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Unasyn","generic_name":"SULBACTAM","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Serine beta-lactamase-like protein LACTB, mitochondrial","drug_class":"beta Lactamase Inhibitor","quality_score":49,"revenue":null,"mechanism":""},{"drug_id":"ocaliva","indication_name":"Primary cholangitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Ocaliva","company_name":"Universitaire Ziekenhuizen KU Leuven","drug_phase":"phase_2","molecular_target":"G-protein coupled bile acid receptor 1, Bile acid receptor","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"gentamicin-sulfate","indication_name":"Cholangitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Gentamicin","generic_name":"Gentamicin Sulfate","company_name":"Merck & Co.","drug_phase":"marketed","molecular_target":"Dihydrofolate reductase","drug_class":"gentamicin","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"elafibranor","indication_name":"Primary biliary cholangitis (PBC)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Iqirvo","generic_name":"ELAFIBRANOR","company_name":"Ipsen","drug_phase":"marketed","molecular_target":"","drug_class":"Peroxisome Proliferator-activated Receptor Agonist [EPC]","quality_score":60,"revenue":null,"mechanism":"Iqirvo works by activating peroxisome proliferator-activated receptors to improve liver function."},{"drug_id":"amikacin","indication_name":"Cholangitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Arikayce Kit","generic_name":"AMIKACIN","company_name":"Bristol-Myers Squibb","drug_phase":"marketed","molecular_target":"","drug_class":"Aminoglycoside Antibacterial","quality_score":10,"revenue":null,"mechanism":"Amikacin works by binding to bacterial ribosomes, inhibiting protein synthesis and ultimately killing the bacteria."},{"drug_id":"kanamycin","indication_name":"Cholangitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Kanacin","generic_name":"KANAMYCIN","company_name":"Bristol-Myers Squibb","drug_phase":"marketed","molecular_target":"Gap junction beta-2 protein","drug_class":"Aminoglycoside Antibacterial","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"obeticholic-acid","indication_name":"Primary cholangitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Ocaliva","generic_name":"OBETICHOLIC ACID","company_name":"Intercept Pharms Inc","drug_phase":"marketed","molecular_target":"Bile acid receptor","drug_class":"Farnesoid X Receptor Agonist","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"cephazolin","indication_name":"Cholangitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Cephazolin","company_name":"HaEmek Medical Center, Israel","drug_phase":"phase_1","molecular_target":"Bacterial penicillin-binding protein, Penicillin-binding protein 1A","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"cefazoline","indication_name":"Cholangitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Cefazoline","company_name":"Nantes University Hospital","drug_phase":"marketed","molecular_target":"Bacterial penicillin-binding protein, Penicillin-binding protein 1A","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"fusidic-acid","indication_name":"Cholangitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Ramycin","generic_name":"FUSIDIC ACID","company_name":"","drug_phase":"phase_3","molecular_target":"Bile salt export pump","drug_class":"fusidic acid","quality_score":47,"revenue":null,"mechanism":"Fusidic acid works by inhibiting the function of the bacterial ribosome, preventing the production of essential proteins."}],"pipeline":[],"offLabel":[],"totalMarketed":17,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT05618145","title":"National Database on Primary Sclerosing Cholangitis (PSC)","phase":"","overall_status":"RECRUITING","enrollment_count":6000,"lead_sponsor_name":"University of Milano Bicocca","has_results":false},{"nct_id":"NCT05151809","title":"National Database on Primary Biliary Cholangitis","phase":"","overall_status":"RECRUITING","enrollment_count":6000,"lead_sponsor_name":"University of Milano Bicocca","has_results":false},{"nct_id":"NCT05800171","title":"Efficacy of Single Use Disposable Elevator Cap (DEC) Duodenoscopy","phase":"","overall_status":"UNKNOWN","enrollment_count":5000,"lead_sponsor_name":"Seoul National University Hospital","has_results":false},{"nct_id":"NCT05292872","title":"Real-World Data Study to Evaluate the Effectiveness of OCA on Hepatic Outcomes in PBC Patients","phase":"","overall_status":"COMPLETED","enrollment_count":4577,"lead_sponsor_name":"Intercept Pharmaceuticals","has_results":true},{"nct_id":"NCT07149675","title":"PBC Long-term Outcomes Study","phase":"","overall_status":"RECRUITING","enrollment_count":4000,"lead_sponsor_name":"Beijing Friendship Hospital","has_results":false},{"nct_id":"NCT06519162","title":"Liver-gut Axis Study Through Identification of Liver Disease-specific Microbiome","phase":"","overall_status":"RECRUITING","enrollment_count":3000,"lead_sponsor_name":"Chungnam National University Hospital","has_results":false},{"nct_id":"NCT06670547","title":"Spanish Registry of Quality Indicators and Adverse Events of Endoscopic Retrograde Cholangiopancreatography","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":3000,"lead_sponsor_name":"Germans Trias i Pujol Hospital","has_results":false},{"nct_id":"NCT07449793","title":"Biochemical Response and Clinical Outcomes in Patients With PBC","phase":"","overall_status":"RECRUITING","enrollment_count":3000,"lead_sponsor_name":"RenJi Hospital","has_results":false},{"nct_id":"NCT06197984","title":"Antimicrobial Resistance in Acute Cholangitis","phase":"","overall_status":"RECRUITING","enrollment_count":1700,"lead_sponsor_name":"Emergency County Hospital Pius Brinzeu; Timisoara, Romania","has_results":false},{"nct_id":"NCT05740358","title":"Liver Cirrhosis Network Cohort Study","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":1222,"lead_sponsor_name":"Northwestern University","has_results":false},{"nct_id":"NCT05187312","title":"Registry for Advanced Endoscopy","phase":"","overall_status":"RECRUITING","enrollment_count":1000,"lead_sponsor_name":"Region Stockholm","has_results":false},{"nct_id":"NCT04181138","title":"Primary Sclerosing Cholangitis in Children","phase":"","overall_status":"RECRUITING","enrollment_count":1000,"lead_sponsor_name":"Arbor Research Collaborative for Health","has_results":false},{"nct_id":"NCT05463445","title":"Multicenter Observational Study of PSC and IgG4-SC in China","phase":"","overall_status":"UNKNOWN","enrollment_count":1000,"lead_sponsor_name":"RenJi Hospital","has_results":false},{"nct_id":"NCT05786482","title":"Evidence Based Mental Wellness Programming Online for Adults Across Chronic Physical Conditions","phase":"NA","overall_status":"COMPLETED","enrollment_count":825,"lead_sponsor_name":"University of Alberta","has_results":false},{"nct_id":"NCT05750498","title":"A-LiNK: Improving Outcomes in Autoimmune Liver Disease","phase":"","overall_status":"RECRUITING","enrollment_count":800,"lead_sponsor_name":"Children's Hospital Medical Center, Cincinnati","has_results":false},{"nct_id":"NCT06864195","title":"A Simple Breath Test to Detect Liver Cancer and Monitor Liver Conditions","phase":"","overall_status":"RECRUITING","enrollment_count":750,"lead_sponsor_name":"Imperial College London","has_results":false},{"nct_id":"NCT04385147","title":"Advanced Endoscopy During COVID-19","phase":"","overall_status":"COMPLETED","enrollment_count":670,"lead_sponsor_name":"Al-Azhar University","has_results":false},{"nct_id":"NCT03041662","title":"Surveillance Study for Early Detection of Cholangiocarcinoma (CCA) in Primary Sclerosing Cholangitis (PSC)","phase":"","overall_status":"COMPLETED","enrollment_count":620,"lead_sponsor_name":"Karolinska University Hospital","has_results":false},{"nct_id":"NCT03771547","title":"ERCP in Super-aged Patients Considering Difficult Cannulation: Challenges and Adverse Events","phase":"","overall_status":"COMPLETED","enrollment_count":614,"lead_sponsor_name":"The Second Hospital of Nanjing Medical University","has_results":false},{"nct_id":"NCT05061680","title":"Quick Large Balloon Dilatation for Removal of Large Bile Duct Stones (SHODBADI)","phase":"NA","overall_status":"RECRUITING","enrollment_count":600,"lead_sponsor_name":"Helsinki University Central Hospital","has_results":false},{"nct_id":"NCT04133792","title":"Effect of Simvastatin on the Prognosis of Primary Primary Sclerosing Cholangitis (PSC)","phase":"PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":571,"lead_sponsor_name":"Annika Bergquist","has_results":false},{"nct_id":"NCT06327126","title":"Efficacy and Safety of Single-session Endoscopic Stone Extraction","phase":"","overall_status":"COMPLETED","enrollment_count":563,"lead_sponsor_name":"Beijing Friendship Hospital","has_results":false},{"nct_id":"NCT03146910","title":"Swiss Primary Biliary Cholangitis Cohort Study","phase":"","overall_status":"RECRUITING","enrollment_count":500,"lead_sponsor_name":"Fondazione Epatocentro Ticino","has_results":false},{"nct_id":"NCT05919433","title":"Detection Program for Patients With Primary Biliary Cholangitis Lost in the System","phase":"","overall_status":"RECRUITING","enrollment_count":500,"lead_sponsor_name":"Hospital Mutua de Terrassa","has_results":false},{"nct_id":"NCT05464303","title":"Definition for Biliary Atresia Associated Cholangitis After Surgery","phase":"","overall_status":"UNKNOWN","enrollment_count":500,"lead_sponsor_name":"Nanjing Children's Hospital","has_results":false},{"nct_id":"NCT04735224","title":"Complications After Endoscopic Retrograde Cholangiopancreatography","phase":"","overall_status":"COMPLETED","enrollment_count":500,"lead_sponsor_name":"Juan Carlos Martín del Olmo","has_results":false},{"nct_id":"NCT02601417","title":"The Necessity of Bile Cultures in Patients With Acute Cholangitis","phase":"NA","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":440,"lead_sponsor_name":"Seoul National University Hospital","has_results":false},{"nct_id":"NCT05750966","title":"Short-course Antibiotics vs Standard Course Antibiotics in Patients With Cholangitis","phase":"NA","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":440,"lead_sponsor_name":"Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)","has_results":false},{"nct_id":"NCT06447168","title":"A Study Observing Everyday Effectiveness and Safety of the Drug Elafibranor in Participants With Primary Biliary Cholangitis Who Are Receiving Ongoing Treatment","phase":"","overall_status":"RECRUITING","enrollment_count":424,"lead_sponsor_name":"Ipsen","has_results":false},{"nct_id":"NCT03890120","title":"Study of Cilofexor in Adults With Primary Sclerosing Cholangitis","phase":"PHASE3","overall_status":"TERMINATED","enrollment_count":419,"lead_sponsor_name":"Gilead Sciences","has_results":true},{"nct_id":"NCT05181332","title":"Predictive Models of Hepatic Decompensation and Survival Outcomes in Pediatric Patients With Cirrhosis","phase":"","overall_status":"UNKNOWN","enrollment_count":400,"lead_sponsor_name":"West China Hospital","has_results":false},{"nct_id":"NCT05925309","title":"Preventive Effect of Prophylactic Oral Antibiotics Against Cholangitis After Kasai Portoenterostomy","phase":"NA","overall_status":"RECRUITING","enrollment_count":356,"lead_sponsor_name":"Children's Hospital of Fudan University","has_results":false},{"nct_id":"NCT07387549","title":"A Study to Assess How Well and Safely Elafibranor Works in Adult Participants With Primary Sclerosing Cholangitis","phase":"PHASE3","overall_status":"NOT_YET_RECRUITING","enrollment_count":350,"lead_sponsor_name":"Ipsen","has_results":false},{"nct_id":"NCT04037007","title":"Efficacy of Fistulotomy for Biliary Cannulation","phase":"NA","overall_status":"RECRUITING","enrollment_count":320,"lead_sponsor_name":"Coordinación de Investigación en Salud, Mexico","has_results":false},{"nct_id":"NCT06011941","title":"Modified Laparoscopic Transcystic Biliary Drainage in the Management of Cholecystocholedocholithiasis","phase":"NA","overall_status":"NOT_YET_RECRUITING","enrollment_count":310,"lead_sponsor_name":"Peking University Third Hospital","has_results":false},{"nct_id":"NCT05920954","title":"Urgent (<24 Hours) Versus Early (24 to 48 Hours) ERCP for Patients With Mild and Moderate Acute Cholangitis","phase":"NA","overall_status":"COMPLETED","enrollment_count":304,"lead_sponsor_name":"Asian Institute of Gastroenterology, India","has_results":false},{"nct_id":"NCT03322943","title":"The Comparison About the Response of Ursodeoxycholic Acid in Primary Biliary Cholangitis Only and Primary Biliary Cholangitis With High Immune Globulin G or Aminotransferase at West China Hospital","phase":"","overall_status":"COMPLETED","enrollment_count":300,"lead_sponsor_name":"West China Hospital","has_results":false},{"nct_id":"NCT04753996","title":"Characterization of Biliary Cell-derived Organoids From Bile of PSC and Non-PSC Patients","phase":"","overall_status":"RECRUITING","enrollment_count":300,"lead_sponsor_name":"Mayo Clinic","has_results":false},{"nct_id":"NCT06016842","title":"A Long-Term Study of Elafibranor in Adult Participants With Primary Biliary Cholangitis","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":276,"lead_sponsor_name":"Ipsen","has_results":false},{"nct_id":"NCT03602560","title":"ENHANCE: Seladelpar in Subjects With Primary Biliary Cholangitis (PBC) and an Inadequate Response to or an Intolerance to Ursodeoxycholic Acid (UDCA)","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":265,"lead_sponsor_name":"Gilead Sciences","has_results":true},{"nct_id":"NCT03610308","title":"ESTES Snapshot Audit 2018","phase":"","overall_status":"COMPLETED","enrollment_count":250,"lead_sponsor_name":"European Society for Trauma and Emergency Surgery","has_results":false},{"nct_id":"NCT06591468","title":"A Multicenter, Randomized, Controlled Trial of Prednisone Combined With Ursodeoxycholic Acid in the Treatment of Primary Biliary Cholangitis With Moderate to Severe Interface Hepatitis Characteristics","phase":"PHASE2, PHASE3","overall_status":"ENROLLING_BY_INVITATION","enrollment_count":244,"lead_sponsor_name":"Han Ying","has_results":false},{"nct_id":"NCT01672853","title":"Simtuzumab (GS-6624) in the Prevention of Progression of Liver Fibrosis in Adults With Primary Sclerosing Cholangitis (PSC)","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":235,"lead_sponsor_name":"Gilead Sciences","has_results":true},{"nct_id":"NCT03831529","title":"Outcomes of Elderly Patients Admitted to the Intensive Care Unit With Severe Acute Cholangitis","phase":"","overall_status":"COMPLETED","enrollment_count":204,"lead_sponsor_name":"Central Hospital, Nancy, France","has_results":false},{"nct_id":"NCT03337074","title":"Paternally Inherited Phenotypes in Cholestasis","phase":"","overall_status":"UNKNOWN","enrollment_count":200,"lead_sponsor_name":"Guy's and St Thomas' NHS Foundation Trust","has_results":false},{"nct_id":"NCT03087656","title":"Antibiotics to Decrease Post ERCP Cholangitis","phase":"PHASE4","overall_status":"UNKNOWN","enrollment_count":200,"lead_sponsor_name":"University of Southern California","has_results":false},{"nct_id":"NCT03754491","title":"The Comparisons of One-stage Stone Removal in Mild and Moderate Cholangitis","phase":"NA","overall_status":"COMPLETED","enrollment_count":196,"lead_sponsor_name":"Chang Gung Memorial Hospital","has_results":false},{"nct_id":"NCT05133336","title":"Saroglitazar Magnesium for Treatment of Primary Biliary Cholangitis","phase":"PHASE2, PHASE3","overall_status":"COMPLETED","enrollment_count":196,"lead_sponsor_name":"Zydus Therapeutics Inc.","has_results":false},{"nct_id":"NCT04620733","title":"RESPONSE: Response to Seladelpar in Subjects With Primary Biliary Cholangitis (PBC) and an Inadequate Control to or an Intolerance to Ursodeoxycholic Acid (UDCA)","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":193,"lead_sponsor_name":"Gilead Sciences","has_results":true},{"nct_id":"NCT03104582","title":"Best Biliary Drainage Option in Advanced Klatskin Tumor","phase":"NA","overall_status":"COMPLETED","enrollment_count":180,"lead_sponsor_name":"Hepatopancreatobiliary Surgery Institute of Gansu Province","has_results":false}],"total":50},"guidelines":[],"source":"Drug Landscape verified database"}